Release of proinflammatory cytokines during pediatric cardiopulmonary bypass: Heparin-bonded versus nonbonded oxygenators

Annals of Thoracic Surgery

Volumn 64, Issue 6, 1997, Pages 1790-1794

  Ashraf, Saeed ^a,b   Tian, Yi ^a   Cowan, Dahlia ^a   Entress, Anthony ^a   Martin, Paul G ^a   Watterson, Kevin G ^a  

^a Killingbeck Hospital   (United Kingdom)

^b LEEDS GENERAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT; CYTOKINE; ELASTASE; HEPARIN; INTERLEUKIN 6; INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CARDIOPULMONARY BYPASS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACORPOREAL CIRCULATION; HUMAN; INFLAMMATION; LEUKOCYTE COUNT; NEWBORN; OXYGENATOR; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

CARDIOPULMONARY BYPASS; CHILD, PRESCHOOL; COMPLEMENT MEMBRANE ATTACK COMPLEX; HEPARIN; HUMANS; INFANT; INFANT, NEWBORN; INTERLEUKIN-6; INTERLEUKIN-8; LEUKOCYTE COUNT; LEUKOCYTE ELASTASE; OXYGENATORS; PROSPECTIVE STUDIES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0031407209     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0003-4975(97)00846-1     Document Type: Article

References (24)

1. Kirklin JK, Westaby S, Blackstone EH, Kirklin JW, Chenoweth DE, Pacifico AD. Complement and damaging effects of cardiopulmonary bypass. J Thorac Cardiovasc Surg. 86:1983;845-857.
2. Steinberg JB, Kapelanski DP, Olson JD, Weiler JM. Cytokine and complement levels in patients undergoing cardiopulmonary bypass. J Thorac Cardiovasc Surg. 106:1993;1008-1016.
3. Kawamura T, Wakusawa R, Okada K, Inada S. Elevation of cytokines during open heart surgery with cardiopulmonary bypass participation of interleukin-8 and 6 in reperfusion injury . Can J Anaesth. 40:1993;1016-1021.
4. Finn A, Naik S, Nigel K, Levinsky RJ, Strobel S, Elliott M. Interleukin-8 release and neutrophil degranulation after paediatric cardiopulmonary bypass. J Thorac Cardiovasc Surg. 105:1993;234-241.
5. Kalfin RE, Engelman RM, Rousou JA, et al. Induction of interleukin-8 expression during cardiopulmonary bypass. Circulation. 88:1993;401-406.
6. Hennein HA, Ebba H, Rodriguez JR, et al. Relationship of the proinflammatory cytokines to myocardial ischemia and dysfunction after uncomplicated coronary revascularization. J Thorac Cardiovasc Surg. 108:1994;626-635.
7. Bando K, Pillai R, Cameron DE. Leukocyte depletion ameliorates free radical mediated lung injury after cardiopulmonary bypass. J Thorac Cardiovasc Surg. 99:1990;873-877.
8. Jansen NJ, van Oeveren W, van den Broek L, et al. Inhibition by dexamethasone of the reperfusion phenomena in cardiopulmonary bypass. J Thorac Cardiovasc Surg. 102:1991;515-525.
9. Gu YJ, van Oeveren W, Akkerman C, Boonstra PW, Huyzen RJ, Wildevuur CRH. Heparin-coated circuits reduce the inflammatory response to cardiopulmonary bypass. Ann Thorac Surg. 55:1993;917-922.
10. Videm V, Svennevig JL, Fosse E, Semb G, Osterud A, Mollnes T. Reduced complement activation with heparin-coated oxygenator and tubings in coronary bypass operation. J Thorac Cardiovasc Surg. 103:1992;806-813.
11. Jansen PG, Velthuis H, Huybregts RA, et al. Reduced complement activation and improved postoperative performance after cardiopulmonary bypass with heparin-coated circuits. J Thorac Cardiovasc Surg. 110:1995;829-834.
12. Steinberg BM, Grossi E, Schwartz D, et al. Heparin bonding of bypass circuits reduces cytokine release during cardiopulmonary bypass. Ann Thorac Surg. 60:1995;525-529.
13. Edmunds HL, Campbell FW. Platelet function and cardiopulmonary bypass. Gravlee GP, Davis RF, Utley JR. Cardiopulmonary bypass principles and practice . 1993;407-435 Williams & Wilkins, Baltimore.
14. Butler J, Rocker GM, Westaby S. Inflammatory response to cardiopulmonary bypass. Ann Thorac Surg. 55:1993;552-559.
15. Lotz M. Interleukin-6. Cancer Invest. 11:1993;732-742.
16. Damas P, Ledoux D, Nys M, et al. Cytokines serum level during severe sepsis in human IL-6 as a marker of severity. Ann Surg. 215:1992;356-362.
17. Moore FD, Warner KG, Assousa S, Valeri CR, Khuri SF. The effect of complement activation during cardiopulmonary bypass. Ann Surg. 208:1988;95-103.
18. Mollnes TE, Videm V, Riesenfeld J, et al. Complement activation and bioincompatibility the terminal complement complex for evaluation, and surface modification with heparin for improvement of biomaterials . Clin Exp Immunol. 88:(Suppl 1):1991;21-26.
19. Deppisch R, Schmitt V, Bommer J, Hansch GM, Ritz E, Rautenberg EW. Fluid phase generation of terminal complement complex as a novel index of bioincompatibility. Kidney Int. 37:1990;696-706.
20. Boackle RJ, Caughman GB, Vesely J, Medgyeshi G, Fudenberg HH. Potentiation of factor H by heparin a rate limiting mechanism for inhibition of the alternative complement pathways . Mol Immunol. 20:1983;1157-1164.
21. Maillet F, Kazatchkine MD, Glotz D, Fischer E, Rowe M. Heparin prevents the formation of human C3 amplification convertase by inhibiting the binding site for B on C3b. Mol Immunol. 20:1983;1401-1404.
22. Videm V, Mollnes TE, Garred P, Svennevig JL. Biocompatibility of extracorporeal circulation in vitro comparison of heparin-coated and uncoated oxygenator circuits . J Thorac Cardiovasc Surg. 101:1991;654-660.
23. Wachtfogel YT, Kucich U, Greenplate J, et al. Human neutrophil degranulation during extracorporeal circulation. Blood. 69:1987;324-330.
24. Bazzoni F, Cassatella MA, Rossi F, Ceska M, Dewald B, Baggiolini M. Phagocytosing neutrophils produce and release high amounts of the neutrophil-activating peptide 1/interleukin 8. J Exp Med. 173:1991;771-774.